Anti-TTF-1 (Thyroid Transcription Factor 1) is useful in differentiating primary adenocarcinoma of the lung from metastatic carcinomas originating in the organs rather than thyroid, germ cell tumors3, and malignant mesothelioma. It can also be used to differentiate small cell lung carcinoma from lymphoid infiltrates. TTF-1 labeling is also seen in thyroid and thyroid-derived tumors. TTF-1 immunostaining is useful in the differentiation between pulmonary and nonpulmonary origin of adenocarcinomas in malignant effusions. TTF-1 staining is very reliable in discerning whether a brain metastasis has arisen from a pulmonary or nonpulmonary site, particularly when dealing with adenocarcinomas and large-cell carcinomas.
Anti-TTF-1 (Thyroid Transcription Factor 1) is useful in differentiating primary adenocarcinoma of the lung from metastatic carcinomas originating in the organs rather than thyroid, germ cell tumors3, and malignant mesothelioma. It can also be used to differentiate small cell lung carcinoma from lymphoid infiltrates. TTF-1 labeling is also seen in thyroid and thyroid-derived tumors. TTF-1 immunostaining is useful in the differentiation between pulmonary and nonpulmonary origin of adenocarcinomas in malignant effusions. TTF-1 staining is very reliable in discerning whether a brain metastasis has arisen from a pulmonary or nonpulmonary site, particularly when dealing with adenocarcinomas and large-cell carcinomas.
http://www.cellmarque.com/Cell Marque
Anti-TTF-1 (Thyroid Transcription Factor 1) is useful in differentiating primary adenocarcinoma of the lung from metastatic carcinomas originating in the organs rather than thyroid, germ cell tumors3, and malignant mesothelioma. It can also be used to differentiate small cell lung carcinoma from lymphoid infiltrates. TTF-1 labeling is also seen in thyroid and thyroid-derived tumors. TTF-1 immunostaining is useful in the differentiation between pulmonary and nonpulmonary origin of adenocarcinomas in malignant effusions. TTF-1 staining is very reliable in discerning whether a brain metastasis has arisen from a pulmonary or nonpulmonary site, particularly when dealing with adenocarcinomas and large-cell carcinomas.
